Вітамін D3 1,25-Дигідроксивітамін D (Vitamin D3 1,25-Dihydroxyvitamin D)

Референтні значення:

Біологічно активна форма вітаміну D – 1,25-дигідроксивітамін D (1,25 (OH) 2 D). Вимірювання рівня сироватки 1,25 (OH) 2 D слід розглянути при підозрі на дефіцит або надлишок цієї форми вітаміну.

Референтні діапазони для 1,25 (OH) 2 D можуть повідомлятися як pg / mL або pmol / L. Молекулярна маса 1,25 (OH) 2 D становить приблизно 416,7, отримуючи такі коефіцієнти перетворення: 1 пмоль / л = 0,42 пг / мл; навпаки, 1 пг / мл = 2,4 пмоль / л.

Референтні діапазони для 1,25 (OH) 2 D[1]:

  • Чоловіки: 18-64 пг / мл
  • Жінки: 18-78 пг / мл

ДЖЕРЕЛА:

  1. Pagana KD, Pagana TJ, Pagana TN. Mosby’s Diagnostic & Laboratory Test Reference. 14th ed. St. Louis, Mo: Elsevier; 2019.
  2. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney International. 2007. 71(1):31-8.
  3. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. July 2005. 16(7):2205-15.
  4. Kitanaka S, Takeyama K, Murayama A, Kato S. The molecular basis of vitamin D-dependent rickets type I. Endocr J. 2001. 48(4):427.
  5. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide over expressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001 Feb. 86(2):497-500.
  6. Ruppe MD, Brosnan PG, Au KS, Tran PX, Dominguez BW, Northrup H. Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets. Clin Endocrinol (Oxf). 2011 Mar. 74(3):312-8.
  7. Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy WA Jr, Gagel RF, et al. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocrine Practice. 2008 Dec. 14(9):1108-14.
  8. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. Dusso AS HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003 Mar 7. 17(4):513-20.
  9. Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010 Nov 27. 24(18):2827-33.
  10. Bouillon RA, Auwerx JH, Lissens WD, Pelemans WK. Vitamin D status in the elderly: seasonal substrate deficiency causes 1,25-dihydroxycholecalciferol deficiency. Am J Clin Nutr. 1987 Apr. 45(4):755-63.
  11. Inui N, Murayama A, Sasaki S, Suda T, Chida K, Kato S, et al. Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med. 2001. 110(9):687-93.
  12. Lut Overbergh, Katinka Stoffels,Mark Waer, Annemieke Verstuyf, Roger Bouillon, and Chantal Mathieu. Immune Regulation of 25-Hydroxyvitamin D-1- alpha Hydroxylase in Human Monocytic THP1 Cells: Mechanisms of Interferon-Mediated Induction. J Clin Endocrinol Metab. 2006 Sep. 91(9):3566-74.
  13. Malloy PJ, Feldman D. Genetic disorders and defects in vitamin d action. Endocrinol Metab Clin North Am. 2010. 39(2):333-36.
  14. Malloy PJ, Eccleshall TR, Gross C, Van Maldergem L, Bouillon R, Feldman D. D Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. J Clin Invest. 1997 Jan. 99(2):297-304.
  15. Brumbaugh PF, Haussler DH, Bressler R, Haussler MR. Radioreceptor assay for 1α,25-dihydroxyvitamin D3. Science ;183:. 1974. 183(4129):1089–1091.
  16. Reinhardt TA, Horst RL, Orf JW, Hollis BW. A microassay for 1,25-dihydroxyvitamin D notrequiring high performance liquid chromatography: Application to clinical studies. Journal of Clinical Endocrinology and Metabolism ;. 1984. 58(1):91–98.
  17. Bruce W. Hollis and Ronald L. Horst. The Assessment of Circulating 25(OH)D and 1,25(OH)2D: Where We Are and Where We Are Going. J Steroid Biochem Mol Biol. 2007 March. 103(3-5):473–476.
  18. Clemens TL, Hendy GN, Graham RF, Baggiolini EG, Uskokovic MR, O’Riordan JLH. A radioimmunoassay for 1,25-dihydroxycholecalciferol. Clinical Science and Molecular Medicine. 1978. 54(3):329–332.
  19. Hollis BW, Kamerud JQ, Kurkowski A, Beaulieu J, Napoli JL. Quantification of circulating 1,25- dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer. Clinical Chemistry. 1996;. 42(4):586–592.
  20. B. Maestro, S. Molero, S. Bajo, N. D´avila, and C. Calle. Transcriptional activation of the human insulin receptorgene by 1,25-dihydroxyvitamin D3. Cell Biochemistry and Function. 2002. 20(3):227–232.
  21. AU PriéD, Friedlander G SO. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clin J Am Soc Nephrol. 2010. 5(9):1717-22.
  22. Lagunova Z, Porojnicu AC, Vieth R, Lindberg FA, Hexeberg S, Moan J. Serum 25-hydroxyvitamin D is a predictor of serum 1,25-dihydroxyvitamin D in overweight and obese patients. J Nutr. 2011 Jan. 141(1):112-7.

Залишити коментар

Ваша e-mail адреса не оприлюднюватиметься. Обов’язкові поля позначені *